GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $4,451,206.62 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,551 shares of GeneDx stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $95.62, for a total value of $4,451,206.62. Following the completion of the transaction, the chief executive officer now owns 48,314 shares of the company’s stock, valued at approximately $4,619,784.68. The trade was a 49.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The stock was sold at an average price of $89.44, for a total value of $96,416.32.
• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Trading Down 2.3 %

Shares of WGS stock opened at $92.20 on Friday. The firm has a market capitalization of $2.59 billion, a PE ratio of -47.04 and a beta of 1.91. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 1 year low of $8.53 and a 1 year high of $115.60. The stock has a fifty day moving average of $87.28 and a two-hundred day moving average of $74.20.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. The business had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, research analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in WGS. Barclays PLC boosted its stake in GeneDx by 346.3% during the 3rd quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of GeneDx in the third quarter valued at $325,000. Charles Schwab Investment Management Inc. boosted its stake in GeneDx by 304.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after buying an additional 110,666 shares in the last quarter. Franklin Resources Inc. acquired a new position in GeneDx during the third quarter worth about $301,000. Finally, JPMorgan Chase & Co. grew its holdings in GeneDx by 617.3% during the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company’s stock worth $2,214,000 after acquiring an additional 44,889 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the topic of several analyst reports. TD Cowen increased their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.